Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Cancer discovery·2025
Same author

Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric malignancies.

JCI insight·2025
Same author

A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer.

Nature immunology·2024
Same author

A Semiautomated Proteomics and Phosphoproteomics Protocol for the Identification of Novel Therapeutic Targets and Predictive Biomarkers in In Vivo Xenograft Models of Pediatric Cancers.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

Post-COVID-19 approach to teaching an undergraduate laboratory class focused on experimental design and data interpretation.

Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology·2024
Same author

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

The Journal of clinical investigation·2024

Related Experiment Video

Updated: Jan 17, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K

Targeting developmental vulnerabilities in childhood sarcomas.

Elise Young1,2,3,4, Barnaby Kelly1,2, Jason E Cain5,6,7

  • 1Hudson Institute of Medical Research, 27-31 Wright St, Clayton, Victoria, 3168, Australia.

Cancer Metastasis Reviews
|September 22, 2025
PubMed
Summary

Childhood sarcomas are aggressive paediatric solid tumours with poor survival rates. This review explores how disrupted developmental pathways drive sarcoma growth and discusses new therapies targeting these vulnerabilities.

Keywords:
Childhood cancerDevelopmental pathwaysSarcomaSignallingTherapeutics

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Related Experiment Videos

Last Updated: Jan 17, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Area of Science:

  • Pediatric Oncology
  • Developmental Biology
  • Cancer Molecular Mechanisms

Background:

  • Childhood sarcomas are aggressive mesenchymal malignancies, comprising over a third of pediatric solid tumors.
  • Treatment progress has been limited, leading to poor survival and high morbidity in long-term survivors.
  • Paediatric sarcomas originate from developing tissues, sharing features with primitive progenitor cells arrested in developmental windows.

Purpose of the Study:

  • To review the molecular mechanisms driving paediatric sarcomagenesis.
  • To highlight the role of disrupted developmental programming in sarcoma initiation and progression.
  • To discuss emerging therapeutic strategies targeting developmental vulnerabilities in childhood sarcomas.

Main Methods:

  • Review of current literature on paediatric sarcomagenesis.
  • Analysis of molecular mechanisms including epigenetic regulation, embryonic signaling, and growth pathways.
  • Examination of age-specific incidence correlating with tissue development.

Main Results:

  • Distorted developmental programming, including epigenetic dysregulation and aberrant signaling pathways, is central to paediatric sarcomagenesis.
  • Sarcoma incidence patterns reflect age-specific tissue expansion and growth dynamics.
  • Understanding developmental origins offers insights into sarcoma heterogeneity.

Conclusions:

  • Targeting developmental vulnerabilities presents a promising avenue for novel paediatric sarcoma therapies.
  • Further research into the molecular underpinnings of developmental reprogramming is crucial for improving treatment outcomes.
  • New therapeutic strategies aim to exploit the unique developmental dependencies of childhood sarcomas.